Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

SciClone Files China BLA for Neuroblastoma Treatment

publication date: Jul 6, 2021

SciClone Pharma, a Shanghai in-licensing company, filed a China BLA for Danylza® to treat high-risk neuroblastoma. In late 2020, SciClone announced a $120 million agreement to acquire China rights for two neuroblastoma therapies from New York's Y-mAbs. In the US, Danylza® is approved to treat pediatric patients 1 year of age and older along with adult patients who have relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. Danylza® is administered along with granulocyte-macrophage colony-stimulating factor (GM-CSF). More details....

Stock Symbol: (HK: 6600)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.